Despite showing arguable signals of efficacy Uniqure’s Huntington’s disease gene therapy has some fundamental problems.
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Annexon’s failure in geographic atrophy could clear the way for its rivals.
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.